查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370943

子宮肌瘤治療藥物市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、類型、最終用戶、地區、競爭細分

Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Type, By End User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 171 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球子宮肌瘤治療藥物市場估值達到44.2億美元，預計在預測期內大幅成長，預計年複合成長率（CAGR）為4.43%，到2028年預計將達到57.1億美元。這種成長是由重塑市場格局的幾個關鍵因素所推動的。

主要市場促進因素

1. 子宮肌瘤盛行率增加

市場概況
預測期 2024-2028
2022 年市場規模 44.2億美元
2028 年市場規模 57.1億美元
2023-2028 年年複合成長率 4.43%
成長最快的細分市場 促性腺激素釋放激素激動劑
最大的市場 北美洲

子宮肌瘤是生長在子宮內的良性腫瘤，已成為全球女性的重大健康議題。子宮肌瘤的盛行率正在上升，促使醫療保健專業人員、研究人員和政策制定者了解其影響因素。子宮肌瘤，也稱為平滑肌瘤，是在子宮肌肉組織中形成的非癌性生長。它們在孕齡期尤其常見，可能會導致月經大量出血、骨盆腔疼痛和鄰近器官受壓等症狀。近幾十年來，子宮肌瘤的盛行率在全球範圍內穩步上升。這一趨勢是由多種因素複雜的相互作用所驅動的，包括生活方式、飲食習慣、體力活動水平的變化、延遲分娩、荷爾蒙波動和遺傳因素。了解這種增加背後的原因對於解決子宮肌瘤日益增加的負擔和開發有效的治療方案至關重要。

2. 改變治療模式

子宮切除術和子宮肌瘤切除術等傳統外科手術歷來是子宮肌瘤的主要治療方法。然而，隨著創新藥物療法的興起，治療範式發生了顯著轉變。這種轉變是由於對微創治療方案的渴望所推動的，這些治療方案可以保留生育能力、提供更快的恢復時間並最大限度地降低與手術相關的風險。子宮肌瘤治療藥物，也稱為藥物療法，已成為手術的可行替代方案。這些藥物透過調節影響肌瘤生長的荷爾蒙、減輕症狀並減少侵入性手術的需要來發揮作用。這種治療方法的轉變正在改善患者的治療效果，並擴大了治療子宮肌瘤的女性的選擇範圍。

3.良好的監管環境

監管環境在塑造新醫療方法的可用性和可及性方面發揮關鍵作用。子宮肌瘤治療藥物市場受益於鼓勵創新和引入新療法的有利監管環境。監管機構優先考慮子宮肌瘤等對女性健康有重大影響的疾病。為滿足未滿足的醫療需求的藥物授予快速審查途徑，從而加快其開發和核准流程。致力於婦女健康的患者權益團體和組織在提高人們對子宮肌瘤的認知和倡導改進治療方案方面也發揮了至關重要的作用。這種有利的監管環境不僅透過及時提供創新療法使患者受益，而且還激勵製藥公司投資研發。

主要市場挑戰

1. 功效和長期數據

雖然子宮肌瘤治療藥物在緩解症狀方面顯示出希望，但對其長期療效和安全性的質疑仍然存在。臨床試驗的觀察期通常相對較短，因此很難充分了解這些藥物的長期效果。產生可靠的長期資料對於確保患者的健康和對這些治療的信心至關重要。

2. 患者的變異性

子宮肌瘤在大小、位置和患者概況方面表現出相當大的變異性。開發有效針對這種異質性的藥物是一項重大挑戰。個人化醫療方法正在受到關注，但針對個別患者量身定做治療仍然很複雜，可能需要精準醫療的進一步進步。

3. 副作用和耐受性

與任何醫療介入一樣，子宮肌瘤治療藥物也可能有副作用。平衡症狀緩解與潛在不良反應是一項微妙的任務。實現適當的平衡以提供有意義的益處而不引起過度不適對於患者接受和堅持至關重要。

主要市場趨勢

1. 聯合療法

將子宮肌瘤治療藥物與其他干涉措施（例如微創手術或荷爾蒙療法）相結合具有巨大的前景。這些協同方法旨在提供全面的解決方案，從多個角度針對肌瘤，最佳化症狀緩解和長期結果。聯合療法可以為具有不同肌瘤特徵的患者提供量身定做的治療方法，從而提高護理的整體效果。

2. 注重生活品質

除了醫療功效之外，未來的趨勢還強調提高患者的生活品質。子宮肌瘤治療藥物不僅可以緩解症狀，還可以改善整體健康，將是最重要的。製藥公司正在探索滿足更廣泛患者需求的療法，並認知到子宮肌瘤對身體、情緒和社會生活的整體影響。

3. 非荷爾蒙治療選擇

雖然荷爾蒙療法一直是子宮肌瘤治療的支柱，但非荷爾蒙療法也越來越受歡迎。目前正在探索針對參與肌瘤生長的特定細胞途徑而不影響荷爾蒙水平的新藥物。這些非荷爾蒙治療可能為不適合荷爾蒙介入的患者提供替代方案。

細分市場洞察

類型洞察

2022年，黏膜下肌瘤主導全球子宮肌瘤治療藥物市場。黏膜下肌瘤是良性子宮生長物，通常在育齡期出現。然而，從 2023 年到 2030 年，壁內肌瘤類別預計將經歷最高的年複合成長率(CAGR)。

最終用戶行業洞察

零售藥局領域在 2022 年佔據市場主導地位，預計將繼續擴大。零售藥局廣泛提供子宮肌瘤治療的藥物，包括非處方止痛藥、口服藥物和 GnRH 拮抗劑。該細分市場的成長是由患者對安全有效的治療選擇的需求所推動的。

區域洞察

由於肌瘤患病率上升、肌瘤引起的妊娠併發症以及新治療方案的批准，北美引領全球子宮肌瘤治療藥物市場。該地區的醫療保健格局也受到肌瘤高發生率的影響，高達80% 的黑人女性和高達70% 的白人女性在50 歲之前患有肌瘤。人們對肌瘤的認知不斷提高，治療方案不斷擴大，預計將推動北美市場進一步成長。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細目
  • 管道細分（按狀態）
  • 按研究應用分類的管道細分
  • 按地區分類的管道明細
  • 臨床試驗熱圖

第 6 章：全球子宮肌瘤治療藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（促性腺激素釋放激素 (Gnrh) 激動劑、促性腺激素釋放激素 (Gnrh) 拮抗劑、黃體素釋放子宮內避孕器 (Iud) 和避孕藥、非荷爾蒙藥物、其他）
    • 依類型（漿膜下肌瘤、壁內肌瘤、黏膜下肌瘤、帶蒂肌瘤）
    • 按最終用戶（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司分類 (2022)
  • 產品市場地圖
    • 按藥物類別
    • 按類型
    • 按最終用戶
    • 按地區

第 7 章：北美子宮肌瘤治療藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（促性腺激素釋放激素 (Gnrh) 激動劑、促性腺激素釋放激素 (Gnrh) 拮抗劑、黃體素釋放子宮內避孕器 (Iud) 和避孕藥、非荷爾蒙藥物、其他）
    • 依類型（漿膜下肌瘤、壁內肌瘤、黏膜下肌瘤、帶蒂肌瘤）
    • 按最終用戶（醫院藥房、零售藥房、其他）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：歐洲子宮肌瘤治療藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（促性腺激素釋放激素 (Gnrh) 激動劑、促性腺激素釋放激素 (Gnrh) 拮抗劑、黃體素釋放子宮內避孕器 (Iud) 和避孕藥、非荷爾蒙藥物、其他）
    • 依類型（漿膜下肌瘤、壁內肌瘤、黏膜下肌瘤、帶蒂肌瘤）
    • 按最終用戶（醫院藥房、零售藥房、其他）
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 9 章：亞太子宮肌瘤治療藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（促性腺激素釋放激素 (Gnrh) 激動劑、促性腺激素釋放激素 (Gnrh) 拮抗劑、黃體素釋放子宮內避孕器 (Iud) 和避孕藥、非荷爾蒙藥物、其他）
    • 依類型（漿膜下肌瘤、壁內肌瘤、黏膜下肌瘤、帶蒂肌瘤）
    • 按最終用戶（醫院藥房、零售藥房、其他）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 10 章：南美子宮肌瘤治療藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（促性腺激素釋放激素 (Gnrh) 激動劑、促性腺激素釋放激素 (Gnrh) 拮抗劑、黃體素釋放子宮內避孕器 (Iud) 和避孕藥、非荷爾蒙藥物、其他）
    • 依類型（漿膜下肌瘤、壁內肌瘤、黏膜下肌瘤、帶蒂肌瘤）
    • 按最終用戶（醫院藥房、零售藥房、其他）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲子宮肌瘤治療藥物市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（促性腺激素釋放激素 (Gnrh) 激動劑、促性腺激素釋放激素 (Gnrh) 拮抗劑、黃體素釋放子宮內避孕器 (Iud) 和避孕藥、非荷爾蒙藥物、其他）
    • 依類型（漿膜下肌瘤、壁內肌瘤、黏膜下肌瘤、帶蒂肌瘤）
    • 按最終用戶（醫院藥房、零售藥房、其他）
    • 按國家/地區
  • MEA：國家分析
    • 南非子宮肌瘤治療藥物
    • 沙烏地阿拉伯子宮肌瘤治療藥物
    • 阿拉伯聯合大公國子宮肌瘤治療藥物
    • 科威特子宮肌瘤治療藥物

第 12 章：市場動態

  • 促進要素
  • 挑戰

第 13 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 14 章：政策與監管環境

第 15 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第16章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Myovant Sciences Ltd
    • Pfizer Inc
    • Abbvie Inc
    • Ferring BV
    • AstraZeneca Pharmaceuticals LP
    • Bayer AG
    • Amring Pharmaceuticals Inc
    • Watson Pharma Pvt Ltd

第 17 章：策略建議

第 18 章：關於我們與免責聲明

簡介目錄
Product Code: 17232

The Global Uterine Fibroid Treatment Drugs Market reached a valuation of USD 4.42 Billion in 2022 and is poised for substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 4.43% and expected to reach USD 5.71 Billion through 2028. This growth is driven by several key factors reshaping the market landscape.

Key Market Drivers

1. Increasing Prevalence of Uterine Fibroids

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.42 Billion
Market Size 2028USD 5.71 Billion
CAGR 2023-20284.43%
Fastest Growing SegmentGonaditropin releasing hormone ag0nists
Largest MarketNorth America

Uterine fibroids, which are benign tumors growing in the uterus, have become a significant global health concern for women. The prevalence of uterine fibroids is on the rise, prompting healthcare professionals, researchers, and policymakers to understand the contributing factors. Uterine fibroids, also known as leiomyomas, are non-cancerous growths that develop in the muscle tissue of the uterus. They are particularly common during the reproductive years and can cause symptoms like heavy menstrual bleeding, pelvic pain, and pressure on adjacent organs. In recent decades, the prevalence of uterine fibroids has steadily increased worldwide. This trend is driven by a complex interplay of factors, including changes in lifestyle, dietary habits, physical activity levels, delayed childbirth, hormonal fluctuations, and genetic factors. Understanding the reasons behind this increase is crucial for addressing the growing burden of uterine fibroids and developing effective treatment options.

2. Shifting Treatment Paradigms

Traditional surgical interventions such as hysterectomy and myomectomy have historically been the primary treatments for uterine fibroids. However, there is a notable shift in treatment paradigms as innovative pharmaceutical therapies gain prominence. This shift is driven by the desire for less invasive treatment options that preserve fertility, offer quicker recovery times, and minimize risks associated with surgery. Uterine fibroid treatment drugs, also known as pharmaceutical therapies, have emerged as viable alternatives to surgery. These drugs work by regulating hormones that influence fibroid growth, reducing symptoms, and decreasing the need for invasive procedures. This transformation in treatment approaches is improving patient outcomes and expanding the range of options available to women dealing with uterine fibroids.

3. Favorable Regulatory Environment

The regulatory landscape plays a pivotal role in shaping the availability and accessibility of new medical treatments. The uterine fibroid treatment drugs market benefits from a favorable regulatory environment that encourages innovation and the introduction of novel therapies. Regulatory agencies prioritize conditions like uterine fibroids, which have a significant impact on women's health. Expedited review pathways are granted to drugs addressing unmet medical needs, speeding up their development and approval processes. Patient advocacy groups and organizations dedicated to women's health have also played a crucial role in raising awareness about uterine fibroids and advocating for improved treatment options. This favorable regulatory environment not only benefits patients by providing timely access to innovative therapies but also incentivizes pharmaceutical companies to invest in research and development.

Key Market Challenges

1. Efficacy and Long-Term Data

While uterine fibroid treatment drugs show promise in alleviating symptoms, questions about their long-term efficacy and safety persist. Clinical trials often have relatively short observation periods, making it challenging to fully understand the long-term effects of these drugs. Generating robust long-term data is crucial to ensure patient well-being and confidence in these treatments.

2. Patient Variability

Uterine fibroids exhibit considerable variability in terms of size, location, and patient profiles. Developing drugs that effectively target this heterogeneity is a significant challenge. Personalized medicine approaches are gaining traction, but tailoring treatments to individual patients remains complex and may require further advancements in precision medicine.

3. Side Effects and Tolerability

Like any medical intervention, uterine fibroid treatment drugs can have side effects. Balancing symptom relief with potential adverse effects is a delicate task. Achieving the right balance to provide meaningful benefits without causing undue discomfort is essential for patient acceptance and adherence.

Key Market Trends

1. Combination Therapies

Combining uterine fibroid treatment drugs with other interventions, such as minimally invasive procedures or hormonal therapies, holds immense promise. These synergistic approaches aim to provide comprehensive solutions that target fibroids from multiple angles, optimizing symptom relief and long-term outcomes. Combination therapies can offer tailored treatments for patients with varying fibroid characteristics, enhancing the overall effectiveness of care.

2. Focus on Quality of Life

Beyond medical efficacy, future trends emphasize enhancing patients' quality of life. Uterine fibroid treatment drugs that not only alleviate symptoms but also improve overall well-being will be at the forefront. Pharmaceutical companies are exploring therapies that address a broader spectrum of patient needs, acknowledging the holistic impact of uterine fibroids on physical, emotional, and social aspects of life.

3. Non-Hormonal Treatment Options

While hormonal therapies have been a mainstay in uterine fibroid treatment, non-hormonal options are gaining traction. New drugs that target specific cellular pathways involved in fibroid growth, without affecting hormone levels, are being explored. These non-hormonal treatments may offer alternatives for patients who are not suitable candidates for hormonal interventions.

Segmental Insights

Type Insights

In 2022, submucosal fibroids dominated the global uterine fibroid treatment drugs market. Submucosal fibroids are benign uterine growths that often manifest during reproductive years. However, the intramural fibroids category is expected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030. Intramural fibroids

are known to drastically affect fertility outcomes, making their treatment a priority.

End User Industry Insights

The retail pharmacies segment dominated the market in 2022 and is expected to continue expanding. Retail pharmacies offer widespread availability of pharmaceuticals used in uterine fibroid treatment, including over-the-counter pain drugs, oral treatments, and GnRH antagonists. This segment's growth is driven by the demand for safe and efficient treatment choices among patients.

Regional Insights

North America leads the global uterine fibroid treatment drugs market due to the rising prevalence of fibroids, pregnancy complications caused by fibroids, and the approval of new treatment options. The region's healthcare landscape is also influenced by the high incidence of fibroids, with up to 80% of Black women and up to 70% of White women experiencing fibroids by the age of 50. The increasing awareness of fibroids and expanding treatment options are expected to fuel further market growth in North America.

Key Market Players

  • Myovant Sciences Ltd
  • Pfizer Inc
  • Abbvie Inc
  • Ferring BV
  • AstraZeneca Pharmaceuticals LP
  • Bayer AG
  • Amring Pharmaceuticals Inc
  • Watson Pharma Pvt Ltd

Report Scope:

In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Uterine Fibroid Treatment Drugs Market, By Drug Class:

  • Gonadotropin-Releasing Hormone (Gnrh) Agonists
  • Gonadotropin-Releasing Hormone (Gnrh) Antagonists
  • Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
  • Non-Hormonal Medications
  • Others

Uterine Fibroid Treatment Drugs Market, By Type:

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroid Treatment Drugs Market, By End User:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroid Treatment Drugs Market, By region:

  • North America
  • United States
  • Mexico
  • Canada
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Uterine Fibroid Treatment Drugs Market.

Available Customizations:

  • Global Uterine Fibroid Treatment Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Uterine Fibroid Treatment Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 6.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 6.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Product Market Map
    • 6.3.1. By Drug Class
    • 6.3.2. By Type
    • 6.3.3. By End User
    • 6.3.4. By Region

7. North America Uterine Fibroid Treatment Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 7.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 7.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User

8. Europe Uterine Fibroid Treatment Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 8.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 8.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Asia-Pacific Uterine Fibroid Treatment Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 9.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 9.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Korea Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User
    • 9.3.4. Japan Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Type
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Type
        • 9.3.5.2.3. By End User

10. South America Uterine Fibroid Treatment Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 10.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 10.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Middle East and Africa Uterine Fibroid Treatment Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 11.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 11.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Type
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Type
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Type
        • 11.3.3.2.3. By End User
    • 11.3.4. Kuwait Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Class
        • 11.3.4.2.2. By Type
        • 11.3.4.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Policy & Regulatory Landscape

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Company Snapshot
  • 16.3. Products & Services
  • 16.4. Financials (In case of listed companies)
  • 16.5. Recent Developments
  • 16.6. SWOT Analysis
    • 16.6.1. Myovant Sciences Ltd
    • 16.6.2. Pfizer Inc
    • 16.6.3. Abbvie Inc
    • 16.6.4. Ferring BV
    • 16.6.5. AstraZeneca Pharmaceuticals LP
    • 16.6.6. Bayer AG
    • 16.6.7. Amring Pharmaceuticals Inc
    • 16.6.8. Watson Pharma Pvt Ltd

17. Strategic Recommendations

18. About Us & Disclaimer